Product quality of parenteral vancomycin products in the United States

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2819-2823

  Nambiar, S ^a   Madurawe, R D ^a   Zuk, S M ^a   Khan, S R ^a   Ellison, C D ^a   Faustino, P J ^a   Mans, D J ^a   Trehy, M L ^a   Hadwiger, M E ^a   Boyne II, M T ^a   Biswas, K ^a   Cox, E M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GENERIC DRUG; VANCOMYCIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIUM CULTURE; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG INFUSION; DRUG PURITY; DRUG QUALITY; FOOD AND DRUG ADMINISTRATION; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UNITED STATES; VALIDATION STUDY;

CONSUMER PRODUCT SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VANCOMYCIN;

EID: 84861133105     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05344-11     Document Type: Article

References (18)

1. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(3).
2. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a).
3. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(9)(iii).
4. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(9).
5. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.94(a)(9)(i) [citing 21 CFR 314.50(d)(1)].
6. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.97.
7. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. 21 CFR 314.70.
8. Code of Federal Regulations. 2011. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 320. Bioavailability and bioequivalence requirements. 21 CFR 320.1(c).
9. Diana J, Visky D, Hoogmartens J, Van Schepdael A, Adams E. 2006. Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 20:685-693. (Pubitemid 43236858)
10. Food and Drug Administration. Accessed 5 July 2011. Approved drug products with therapeutic equivalence evaluations, 31st ed (orange book). Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/UCM071436.pdf.
11. Hadwiger ME, Sommers CD, Mans DJ, Patel V, Boyne MT II. 2012. Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays. Antimicrob. Agents Chemother. 56:2824-2830.
12. Harris CM, Kopecka H, Harris TM. 1983. Vancomycin: structure and transformation to CDP-1. J. Am. Chem. Soc. 105:6915-6922.
13. Marshall FJ. 1965. Structure studies on vancomycin. J. Med. Chem. 8:18-22.
14. Nagarajan R. 1991. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob. Agents Chemother. 35:605-609.
15. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. 2010. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect. Dis. 10:153.
16. United States Pharmacopeial Convention. 2011. The United States pharmacopeia 34 - the national formulary 29. United States Pharmacopeial Convention, Rockville, MD.
17. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271-3279.
18. Zuluaga AF, et al. 2010. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 5:e10744.